News & Updates

Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.

Use of the selective JAK1 inhibitor SHR0302 significantly improves the clinical signs and symptoms of patients with moderate-to-severe active rheumatoid arthritis (RA) who had shown poor response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to a study presented at EULAR 2024.

A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.

In patients with type 1 diabetes (T1D) treated with SGLT2 inhibitors, such as dapagliflozin, the addition of pioglitazone helps to intensify the reduction in HbA1c and blocks the increase in plasma ketone driven by SGLT2 inhibitors, reports a study presented at ADA 2024. This enables long-term cardiovascular and renal outcome studies to be safely performed in T1D patients.

Use of antibiotics appears to increase the risk of Kawasaki disease (KD) in children, reveals a study. KD development is potentially driven by gut microbiota changes due to antibiotic use.

Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation.